Did CATIE influence antipsychotic use?
Citrome
Leslie
L
Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA. citrome@nki.rfmh.org
Jaffe
Ari
A
Martello
David
D
Allingham
Baerbel
B
Levine
Jerome
J
D014150:Antipsychotic Agents / Q000191:economics* / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000191:economics / Q000627:therapeutic use; D003024:Clozapine / Q000191:economics / Q000627:therapeutic use; D003987:Dibenzothiazepines / Q000191:economics / Q000627:therapeutic use; D004358:Drug Therapy / Q000706:statistics & numerical data*; D006220:Haloperidol / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D000077152:Olanzapine; D010546:Perphenazine / Q000191:economics / Q000627:therapeutic use; D010879:Piperazines / Q000191:economics / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000191:economics*; D000069348:Quetiapine Fumarate; D018967:Risperidone / Q000191:economics / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy* / Q000191:economics*; D013844:Thiazoles / Q000191:economics / Q000627:therapeutic use
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D010879:Piperazines; D013844:Thiazoles; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; C092292:ziprasidone; D010546:Perphenazine; D003024:Clozapine; D006220:Haloperidol; D018967:Risperidone; D000077152:Olanzapine